Ameriprise’s Opus Genetics IRD Stock Holding History

Ameriprise’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.77M	Buy	+388,491	New	+$1.34M	﹤0.01%	3016
2022 Q4	–	Sell	-30,099	Closed	-$60K	–	4063
2022 Q3	$60K	Hold	30,099	–	–	﹤0.01%	3882
2022 Q2	$58K	Buy	30,099 +251	+0.8%	+$571	﹤0.01%	3820
2022 Q1	$97K	Buy	+29,848	New	+$102K	﹤0.01%	3849
2014 Q4	–	Sell	-3	Closed	-$1K	–	4470
2014 Q3	$1K	Hold	3	–	–	﹤0.01%	5594
2014 Q2	$1K	Buy	+3	New	+$1.36K	﹤0.01%	5389

Other funds holding IRD

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ameriprise's IRD Position: Q1 2026 in Review

Ameriprise opened a new position in Opus Genetics (IRD) in Q1 2026: 388,491 shares worth $1.77M. The stake represents ﹤0.01% of the portfolio and ranks #3016 among its holdings. This is a return to the name: Ameriprise previously reported a position in IRD as recently as Q3 2022.

Ameriprise first reported a position in IRD in Q2 2014 and has held it in 6 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

Ameriprise held 388,491 shares of Opus Genetics worth $1.77M as of Q1 2026.
Opus Genetics was a new Ameriprise position in Q1 2026.
Opus Genetics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3016 holding.
Ameriprise first reported a position in Opus Genetics in Q2 2014 and has held it in 6 quarters since.
79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.